1. Insmed will present at the BofA Health Care Conference on May 13, 2025. 2. The presentation will cover their advanced therapies for serious diseases. 3. Insmed is recognized for its employer reputation in the biopharmaceutical industry. 4. Their focus includes pulmonary conditions and investigational medicines. 5. Webcast will be available for 30 days post-event on their website.
A presentation at a major healthcare conference can boost investor confidence. Historical instances show that such events often lead to positive price movements for biopharmaceutical companies.
The announcement of a conference presentation can signal upcoming developments and attract investor attention. It indicates proactive engagement with the market and potential updates on product pipelines.
The conference is on May 13, prompting immediate market reactions. Investors tend to react quickly to insights shared during such events.
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT.
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
[email protected]
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
[email protected]
SOURCE Insmed Incorporated